Next-generation sequencing for identifying pyrazinamide resistance in mycobacterium tuberculosis

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 903-904

  Daum, Luke T ^a   Fourie, P B ^b   Bhattacharyya, Sanjib ^c   Ismail, Nazir A ^d   Gradus, Steve ^c   Maningi, Nontuthuko E ^b,e   Omar, Shaheed V ^d   Fischer, Gerald W ^a  

^a Longhorn Vaccines and Diagnostics   (United States)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c City of Milwaukee Health Department   (United States)

^d National Institutefor Communicable Diseases   (United Kingdom)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; GENE MUTATION; LETTER; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84895744396     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit811     Document Type: Letter

References (7)

1. Kurbatova EV, Cavnaugh JS, Dalton T, Click ECegielski JP. Epidemiology of pyrazinamideresistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 2013; 57:1081-93.
2. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actimomycetes; approved standard. Document M24-A2. Wayne, PA: CLSI, 2011.
3. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2010; 48:300-1.
4. Daum LT, Rodriguez JD, Worthy SA, et al. Next-generation Ion Torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol 2012; 50: 3831-7.
5. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51:42-9.
6. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70:748-54.
7. Daum LT, Fischer GW, Sromek J, et al. Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants residing in the USA using Ion Torrent full-gene sequencing. Epidemiol Infect 2013; 27:1-6.